Lbp Am Sa Acquires 3,116 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Lbp Am Sa grew its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 6.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 49,913 shares of the medical device company’s stock after acquiring an additional 3,116 shares during the quarter. Lbp Am Sa’s holdings in Cooper Companies were worth $4,589,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of COO. Covestor Ltd boosted its position in shares of Cooper Companies by 144.9% in the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 200 shares during the period. Ashton Thomas Securities LLC bought a new stake in shares of Cooper Companies in the third quarter valued at about $25,000. GSA Capital Partners LLP boosted its position in shares of Cooper Companies by 150.6% in the third quarter. GSA Capital Partners LLP now owns 6,993 shares of the medical device company’s stock valued at $772,000 after acquiring an additional 4,202 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Cooper Companies by 1.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 443,863 shares of the medical device company’s stock valued at $48,976,000 after acquiring an additional 6,489 shares during the period. Finally, KBC Group NV boosted its position in shares of Cooper Companies by 5.1% in the third quarter. KBC Group NV now owns 258,460 shares of the medical device company’s stock valued at $28,519,000 after acquiring an additional 12,435 shares during the period. Institutional investors own 24.39% of the company’s stock.

Analysts Set New Price Targets

COO has been the subject of a number of analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $115.00 price target (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Stifel Nicolaus dropped their price target on Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. JPMorgan Chase & Co. dropped their price target on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Finally, Wells Fargo & Company boosted their price target on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $111.89.

Cooper Companies Stock Up 4.5 %

Shares of NASDAQ COO opened at $81.22 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The company has a market cap of $16.21 billion, a price-to-earnings ratio of 41.65, a PEG ratio of 2.25 and a beta of 1.02. The Cooper Companies, Inc. has a 12 month low of $77.05 and a 12 month high of $112.38. The stock has a 50-day moving average price of $91.20 and a two-hundred day moving average price of $98.86.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. As a group, analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.